Handelsbanken Fonder AB Acquires 931,300 Shares of Cellebrite DI Ltd. $CLBT

Handelsbanken Fonder AB boosted its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 61.3% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,450,000 shares of the company’s stock after acquiring an additional 931,300 shares during the quarter. Handelsbanken Fonder AB owned about 1.02% of Cellebrite DI worth $39,200,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Signaturefd LLC boosted its holdings in shares of Cellebrite DI by 68.3% in the 2nd quarter. Signaturefd LLC now owns 2,019 shares of the company’s stock worth $32,000 after purchasing an additional 819 shares during the period. Bosun Asset Management LLC increased its position in Cellebrite DI by 2.5% during the first quarter. Bosun Asset Management LLC now owns 44,376 shares of the company’s stock valued at $862,000 after acquiring an additional 1,069 shares during the last quarter. Fox Run Management L.L.C. raised its stake in shares of Cellebrite DI by 3.9% in the second quarter. Fox Run Management L.L.C. now owns 30,359 shares of the company’s stock valued at $486,000 after acquiring an additional 1,127 shares during the period. Advisors Asset Management Inc. raised its stake in shares of Cellebrite DI by 24.7% in the first quarter. Advisors Asset Management Inc. now owns 6,133 shares of the company’s stock valued at $119,000 after acquiring an additional 1,214 shares during the period. Finally, ARK Investment Management LLC lifted its holdings in shares of Cellebrite DI by 1.6% in the 2nd quarter. ARK Investment Management LLC now owns 86,063 shares of the company’s stock worth $1,377,000 after acquiring an additional 1,363 shares during the last quarter. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently commented on CLBT shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellebrite DI in a report on Wednesday. Wall Street Zen downgraded Cellebrite DI from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Lake Street Capital upped their price objective on Cellebrite DI from $22.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Bank of America lifted their target price on Cellebrite DI from $24.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Finally, JPMorgan Chase & Co. upped their price target on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $24.00.

Cellebrite DI Trading Down 3.2%

Shares of Cellebrite DI stock opened at $16.88 on Friday. The firm has a market cap of $4.04 billion, a P/E ratio of -22.21, a P/E/G ratio of 3.16 and a beta of 1.28. Cellebrite DI Ltd. has a 12 month low of $13.10 and a 12 month high of $26.30. The stock’s fifty day moving average price is $17.88 and its 200-day moving average price is $16.62.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings data on Wednesday, November 12th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.05). The business had revenue of $126.03 million during the quarter, compared to analysts’ expectations of $122.98 million. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The firm’s revenue was up 17.9% compared to the same quarter last year. During the same period last year, the company earned $0.14 earnings per share. Cellebrite DI has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.